1h Free Analyst Time
The hematopoietic stem cells transplantation (HSCT) market is forecasted to grow by USD 2.58 billion during 2023-2028, accelerating at a CAGR of 6.64% during the forecast period. The report on the hematopoietic stem cells transplantation (HSCT) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by availability of technologically advanced equipment, increasing investments in field of regenerative medicines, and rising number of HSCT.
The hematopoietic stem cells transplantation (HSCT) market is segmented as below:
By Application
- Bone marrow transplant
- Peripheral blood stem cell transplant
- Cord blood transplant
By Type
- Autologous HSCT
- Allogeneic HSCT
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the hematopoietic stem cells transplantation (HSCT) market covers the following areas:
- Hematopoietic stem cells transplantation (HSCT) market sizing
- Hematopoietic stem cells transplantation (HSCT) market forecast
- Hematopoietic stem cells transplantation (HSCT) market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global hematopoietic stem cells transplantation (HSCT) market: AllCells Corp., Athersys Inc., Beike Biotechnology Co. Ltd., bluebird bio Inc., Cellular Biomedicine Group Inc., FUJIFILM Corp., Gamida Cell Ltd., Lineage Cell Therapeutics Inc., Lonza Group Ltd., MEDIPOST Co. Ltd., Merck and Co. Inc., Mesoblast Ltd., Pluristem Therapeutics Inc., Sanofi SA, Sartorius CellGenix GmbH, Taiga Biotechnologies Inc., Takeda Pharmaceutical Co. Ltd., Talaris Therapeutics Inc., and ThermoGenesis Holdings Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing demand for personalized medicine."
According to the report, one of the major drivers for this market is the availability of technologically advanced equipment.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AllCells Corp.
- Athersys Inc.
- Beike Biotechnology Co. Ltd.
- bluebird bio Inc.
- Cellular Biomedicine Group Inc.
- FUJIFILM Corp.
- Gamida Cell Ltd.
- Lineage Cell Therapeutics Inc.
- Lonza Group Ltd.
- MEDIPOST Co. Ltd.
- Merck and Co. Inc.
- Mesoblast Ltd.
- Pluristem Therapeutics Inc.
- Sanofi SA
- Sartorius CellGenix GmbH
- Taiga Biotechnologies Inc.
- Takeda Pharmaceutical Co. Ltd.
- Talaris Therapeutics Inc.
- ThermoGenesis Holdings Inc.
